company background image
1J5 logo

Hyphens Pharma International Catalist:1J5 Stock Report

Last Price

S$0.28

Market Cap

S$85.0m

7D

-1.8%

1Y

-16.7%

Updated

25 Mar, 2024

Data

Company Financials +

Hyphens Pharma International Limited

Catalist:1J5 Stock Report

Market Cap: S$85.0m

1J5 Stock Overview

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally.

1J5 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends3/6

Hyphens Pharma International Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hyphens Pharma International
Historical stock prices
Current Share PriceS$0.28
52 Week HighS$0.35
52 Week LowS$0.27
Beta0.30
1 Month Change-3.51%
3 Month Change-3.51%
1 Year Change-16.67%
3 Year Change-11.29%
5 Year Change30.95%
Change since IPO0%

Recent News & Updates

Recent updates

Shareholder Returns

1J5SG PharmaceuticalsSG Market
7D-1.8%-1.8%0.8%
1Y-16.7%8.1%-4.9%

Return vs Industry: 1J5 underperformed the SG Pharmaceuticals industry which returned 9.7% over the past year.

Return vs Market: 1J5 underperformed the SG Market which returned -3.8% over the past year.

Price Volatility

Is 1J5's price volatile compared to industry and market?
1J5 volatility
1J5 Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement4.8%
10% most volatile stocks in SG Market14.4%
10% least volatile stocks in SG Market2.2%

Stable Share Price: 1J5 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1J5's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998355See Wah Limhttps://www.hyphensgroup.com

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. The company operates through three segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine through distributorship or licensing, and supply agreements for the therapeutic areas, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedic and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, and family medicine.

Hyphens Pharma International Limited Fundamentals Summary

How do Hyphens Pharma International's earnings and revenue compare to its market cap?
1J5 fundamental statistics
Market capS$85.03m
Earnings (TTM)S$8.57m
Revenue (TTM)S$170.60m

9.9x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1J5 income statement (TTM)
RevenueS$170.60m
Cost of RevenueS$109.57m
Gross ProfitS$61.03m
Other ExpensesS$52.46m
EarningsS$8.57m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.028
Gross Margin35.77%
Net Profit Margin5.02%
Debt/Equity Ratio4.9%

How did 1J5 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

31%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.